PRVA

AI Memo

Privia Health Group

As of 2026-09-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Delivery against raised 2026 outlook • 2026-12-31

Base target: $21 / p=1% prob

Biggest risk

Revenue grew faster than gross profit in Q2, implying gross-margin pressure. The cash-conversion target depends partly on MSSP settlement timing, and $19.4 million of Q2 non-cash stock compensation exceeded $9.0 million of net income [#SEC-8K-2026-08-06].

Invalidation

Break below $14 or thesis failure.

What would change my mind?

Provider and attributed-life growth, higher platform contribution, and raised 2026 expectations support a constructive operating view [#SEC-8K-2026-08-06]. The deterministic score has a positive directional prior, but its catalyst-density score is only 0.5.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-28

Base target

$21

p=1%

Bull target

$27

p=0%

Bear target

$14

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Physician-network and value-based-care scaling
Provider and attributed-life growth, higher platform contribution, and raised 2026 expectations support a constructive operating view [#SEC-8K-2026-08-06].
The deterministic score has a positive directional prior, but its catalyst-density score is only 0.5.

BearKey bullets

Available peers are loose business-model matches, limiting comparative valuation confidence.
Gross profit rose 14.3% versus 21.4% revenue growth in Q2; persistent margin compression could offset network growth [#SEC-8K-2026-08-06].
July Form 4 filings show CFO and director open-market sales; these are a potential sentiment overhang, not evidence of operating deterioration [#SEC-FORM4-2026-07-13] [#SEC-FORM4-2026-07-07].

WatchKey bullets

Delivery against raised 2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $21 (p=1%)

Target spread vs base: +29% / -33%

Scenario probabilities

Bull Target: $27 (p=0%)Base Target: $21 (p=1%)Bear Target: $14 (p=0%)

Commentary

The company-confirmed Q2 growth and raised outlook support a positive operating tone. The September 25 anchor is $19.71, but the packet does not establish the immediate post-release price reaction or whether an initial move held. Confirmed analyst revisions, social coverage, options skew, short interest, and employee sentiment are unavailable; zero-valued sentiment fields represent missing data, not neutral readings. The earnings document labeled as a September investor release is third-party valuation commentary, not a company release.

As of 2026-09-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Physician-network and value-based-care scaling

Scenarios

Bull Target (Scenario probability)

$27 / p=0% prob

Base Target (Scenario probability)

$21 / p=1% prob

Bear Target (Scenario probability)

$14 / p=0% prob

Analysis 2026-09-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Delivery against raised 2026 outlook
Privia reported Q2 revenue of $632.6 million, up 21.4% year over year, and adjusted EBITDA of $37.4 million, up 29.1%. It raised its full-year outlook, including attributed lives to 1.625–1.650 million, while targeting the high end of its prior $2.35–$2.45 billion revenue range. Year-end delivery is the central thesis test; December 31 is a fiscal-year checkpoint, not an announced earnings date [#SEC-8K-2026-08-06].
Prob 70.00% • Move 10.00% • Priced-in 50.00%
EVENT2026-12-31
Free-cash-flow conversion test
Management expects approximately 70–80% of 2026 adjusted EBITDA to convert to free cash flow, subject to the timing of MSSP cash settlement. Cash realization below that expectation would weaken the quality-of-earnings case [#SEC-8K-2026-08-06].
Prob 60.00% • Move 7.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Physician-network and value-based-care scaling
2027-06-30
Q2 implemented providers rose 10.1% to 5,644, attributed lives rose 19.2% to 1.647 million, and platform contribution rose 20.1%. Sustaining those trends could support earnings growth, but this is a monitoring thesis rather than a dated company milestone [#SEC-8K-2026-08-06].
Prob 60% • Move 15% • Priced-in 45%

Risks

Available peers are loose business-model matches, limiting comparative valuation confidence.
Gross profit rose 14.3% versus 21.4% revenue growth in Q2; persistent margin compression could offset network growth [#SEC-8K-2026-08-06].
July Form 4 filings show CFO and director open-market sales; these are a potential sentiment overhang, not evidence of operating deterioration [#SEC-FORM4-2026-07-13] [#SEC-FORM4-2026-07-07].
Substantial stock compensation relative to GAAP net income complicates per-share valuation [#SEC-8K-2026-08-06].
The 2026 free-cash-flow conversion expectation is subject to MSSP cash-settlement timing [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
ACHC	Similar market capitalization and healthcare-services classification, but its behavioral-health facilities make it a loose operating comparison.
CLOV	Value-based-care exposure offers a thematic comparison, but Clover's insurer model is not a direct margin or valuation comparable to Privia's physician-enablement platform.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-28

Loading AI feed…

Symbol

Summary

ACHC

Similar market capitalization and healthcare-services classification, but its behavioral-health facilities make it a loose operating comparison.

CLOV

Value-based-care exposure offers a thematic comparison, but Clover's insurer model is not a direct margin or valuation comparable to Privia's physician-enablement platform.